Login to Download
PDF version

We don’t define ourselves as a company that’s going to be able to take this cardiac opportunity to commercialization, so that will be a perfect opportunity for a cardiac-focused corporation to partner with us. We also have other offerings in spine and nerve regeneration that we most likely will not do ourselves, and these are sizable markets as well.

Q: Please describe the mission/vision of your company:
  A: We believe we are developing a safe and advanced technology in the wound healing and tissue regeneration market with PACE™. We often talk about “Healing today, curing tomorrow” and we don’t take this lightly. We want to develop a long-term platform that meets the immediate need for healing, but also prevents recurrence and the need for later interventions. dermaPACE® is non-invasive and does not require anesthesia, making it a cost-effective, time-efficient and painless approach to wound care. Physicians and nurses look for therapies that can accelerate the healing process and overcome the obstacles of patients' compromised conditions, and they prefer treatments that are easy to administer in addition to being minimally disruptive to the patients or the caregivers’ daily routines.
  We are now entirely focused on developing PACE™ technology to stimulate tissue healing in all wound healing conditions to include diabetic foot ulcers (DFU), decubitus ulcers (pressure sores), burns and other skin eruption conditions, and orthopedic and spine applications such as fracture healing and fusion, and the elimination of chronic pain from trauma or arthritis. In the mid to longer term development, we will focus on plastic and cosmetic applications such as preconditioning for graft and transplant acceptance, skin tightening, scarring and other potential aesthetic uses; and potential developments in cardiac indications for removing plaque due to atherosclerosis and improving blood supply to the heart muscle.

Q: How exactly does your personal vision fit with the company’s goals?
  A: The number one reason I am in the healthcare sector is because I want to make a difference in peoples lives. Here at SANUWAVE our PACE™ platform of products has the chance to do just that. The degenerative conditions and tissue regenerative markets we are addressing have major needs that can benefit from the ability of PACE™ to activate neovascularization, healing, and long-term tissue stability and durability.

Q: Please provide information regarding the company’s market overview:
  A: With respect to wound care, it is a significant opportunity. If you just look at diabetic foot ulcers, there are up to 3 million foot ulcers in any given year. Diabetes is a significant problem in the U.S. There are 27 million people today with diabetes throughout the U.S. and 79 million who are pre-diabetic. So unfortunately, this disease state is only getting worse, and therefore the opportunity and need is large. We define the U.S. dermaPACE® opportunity alone as exceeding $5 billion. We look at the availability of options to meet the entire market need from both a cost and an efficacy standpoint. We feel diabetes and diabetic foot ulcers specifically are underserved from a product-performance perspective. Finally, we have to be able to do something well, to do it efficiently, and to provide it in a manner so both the customer, in this case the caregiver, and the patient are going to want to incorporate it into their standard of care. We think we have this in dermaPACE® and in other planned products in the portfolio.

Q: What products or projects is SANUWAVE working on, on an international scale?
  A: dermaPACE® and orthoPACE™ are in the European market.